Skip to content
request demo
Trusted by 100+ leading biopharma companies

For Business Development & Licensing Teams

AI Agentic Workflows that screen landscapes, build valuations, and track competitors - so your team owns the deep work. Cortellis, Evaluate Pharma, GlobalData, and AlphaSense stop at search. Ferma, the pharma BD intelligence platform, runs the workflow start to finish.
request demo

Deal Flow Is Accelerating. Pharma BD Intelligence Hasn't Kept Pace.

Signal Velocity
 
Clinical readouts, regulatory decisions, and competitive moves reshape asset valuations every week. Emerging biotechs surface faster than any team can evaluate them. China went from marginal to the largest origin of global deal value in five years.
The Grunt Work Problem
 
Your team spends weeks analyzing conference readouts, pipeline movements, and investor reports to assemble one asset evaluation. Legacy pharma licensing intelligence tools provide raw ingredients but do none of the synthesis.
Conviction Timing
 

While your team is still assembling diligence, nimble competitors are already building conviction and initiating term sheets. A delayed thesis is a lost opportunity.

BD Agentic Workflows

Committee-Ready Deliverables for Every Stage of the Deal Cycle
Opp Screener
Opportunity Screener
AI-powered pharma asset screening for inbound or outbound assets, scored against portfolio fit, clinical differentiation, and strategic criteria. From the platform: screened 33,575 drugs to 5 acquirable targets in a single workflow run.
rNPV Valuation Model
rNPV Valuation Model
Bottom-up rNPV valuation model using epidemiology, clinical PoS by phase, pricing benchmarks, and competitive dynamics. Bear/base/bull scenarios. Adjustable inputs. Exportable for finance review.
Deal Comparables Analysis
Deal Comparables Analysis
Pull and structure comparable deals by TA, mechanism, and phase — upfront, milestones, royalty rates, total deal value. Excel workbook ready for the IC deck.
Com Lands
Competitive Drug Landscape
All drugs in a TA — efficacy, safety, deal activity, regulatory status — scored and ranked. Continuously updated.
Pipeline & Catalyst Tracker
Catalyst Tracker & PDUFA Calendar
Track readouts, FDA actions, PDUFA dates, and milestone triggers across your watchlist — auto-updated with competitive context.
Patent Landscape
IP / Patent Landscape
IP patent landscape for pharma BD - expiry dates, freedom-to-operate, IPR challenges, and exclusivity risks - structured brief, not a raw database export.
Evidence Gap Analysis
Evidence Gap Analysis
Map evidence gaps against competitor data packages. Identify where your asset has a differentiation opportunity in the clinical or commercial record.

How Ferma's Pharma BD Intelligence Platform Works

S T E P  1

Define Your Screen Criteria

Target indication, mechanism, deal structure preference, portfolio fit parameters. Your BD methodology, encoded as the Agentic Workflow's plan.

S T E P  2

Composite Screcard

Agents pull from preclinical, clinical, commercial, and regulatory data — apply your encoded instructions — and structure into a composite scorecard automatically.

S T E P  3

Receive Your IC-ready Package

Screener, deal comp workbook, and executive summary — formatted for your licensing committee. Ready to share.

Why BD&L Teams Switch to Ferma

Ferma
Cortellis
 
GlobalData

 
 
Evaluate Pharma

 
 
AlphaSense

 
Data Freshness
 24/7 autonomous
Periodic updates

Analyst-curated, periodic

 Quarterly consensus

Real-time doc search
Output Format
 Finished deliverables Raw exports
 		Pre-built reports/dashboards Spreadsheets/charts AI summaries
Data Interconnectedness
 Asset-centric; fully interconnected, single source of truth Event-level; siloed, no unified data model Company/TA-level; siloed, no unified data model Metric-level; siloed, no unified data model Document-level; siloed, no unified data model
China Coverage
 Native language Limited Some, western lens Western-centric English only
AI Capability
 Multi-step agents Basic filters Basic analytics dashboards No AI layer

LLM search
Clinical Readouts
 Auto-captured, indexed Manual tracking Pipeline tracker + analyst  Not primary focus  Search transcripts
Methodology Custom playbooks Rigid filters Analyst-driven reports Fixed frameworks Keyword/semantic search
3
K
Deals
130
K
Drug Development Programs
400
K
Clinical Trials
quote

Our BD screens used to take two analysts a week to build. Ferma produces the same package — comp scorecard, deal comps, landscape — in a single run. We're evaluating twice as many assets in the same timeframe.

Director
Business Development & Licensing, Large Cap Pharma
CTA Home

Stop Screening on Spreadsheets. Start Moving on Deals.

Talk to a BD&L Expert

Frequently Asked Questions

How is Ferma different from Cortellis or Evaluate Pharma for BD teams?

Cortellis and Evaluate Pharma are data subscriptions - they return structured datasets that BD analysts must extract, model, and format into IC deliverables themselves. Neither runs the workflow end to end. Ferma's BD Agentic Workflows encode the full process: data collection, composite scoring, rNPV financial modeling, and deliverable formatting happen automatically. In one workflow run, Ferma screened 33,575 drugs to 5 committee-ready targets, including composite scorecard, rNPV valuation model, and deal comparables package.

Does Ferma cover China pipeline data for BD teams?

Yes. China went from marginal to the largest origin of global deal value in five years. Ferma monitors Chinese biotech deal sourcing data through native-language trial registries and NMPA filings, a coverage gap that western-centric pharma BD platforms consistently leave open. China pipeline coverage is a core differentiator for BD teams tracking early-stage competitive assets and licensing opportunities.

What does Ferma actually deliver at the end of a BD workflow and in what format?

A BD Agentic Workflow run produces a complete, committee-ready diligence package, not a data export for your team to format. Depending on the workflow stage, that includes a composite scorecard with every score traced to source data, a bottom-up rNPV model with bear/base/bull scenarios exportable to Excel, a deal comparables workbook structured by TA, phase, and mechanism, and an executive summary brief formatted for licensing committee review. All outputs export to PowerPoint, Excel, or PDF and are ready to share without additional formatting. No blank slides. No manual assembly.

What is an rNPV model in pharma licensing?

 rNPV (risk-adjusted Net Present Value) is the standard valuation method pharma BD teams use to assess a pipeline asset or licensing opportunity. It adjusts projected cash flows for clinical and regulatory success probability at each phase, incorporating epidemiology, pricing benchmarks, and competitive dynamics. Ferma's rNPV Valuation Model Agentic Workflow automates this with bear, base, and bull scenarios, exportable for licensing committee review.